ELI LILLY & Co

LLY · NYSE · SIC 2834: Pharmaceutical Preparations · Market Cap: $828.2B · 50,000 employees
70
SEC Filings
$939.47
Close 2026-04-10
50,000
Employees

Business Summary

Eli Lilly and Company, incorporated in 1901 in Indiana, discovers, develops, manufactures, and markets human pharmaceutical products worldwide. Operating in a single business segment, Lilly sells products in approximately 90 countries across therapeutic areas including cardiometabolic health (Mounjaro, Zepbound, Jardiance, Humalog), oncology (Verzenio, Cyramza, Retevmo, Jaypirca), immunology (Ebglyss, Olumiant), and neuroscience. The company manufactures and distributes through facilities in the U.S., Puerto Rico, Europe, and Asia.

Latest Stock Quote

LLY 2026-04-10 $939.47 O:$963.69 H:$963.94 L:$935.54 Vol:2.0M VWAP:$940.8554
origin leaf: b6122d19d0147d1aabb0f04f11200c2c45ba5b17bd9268417c903d0f7531580d

Next Earnings

Q2 FY2026 — expected 2026-08-11

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionLLYdiscussed_in_filing Blockchain & Crypto
topic_mentionLLYdiscussed_in_filing Healthcare & Bio
topic_mentionLLYdiscussed_in_filing Blockchain & Crypto
topic_mentionLLYdiscussed_in_filing Healthcare & Bio
topic_mentionLLYdiscussed_in_filing Blockchain & Crypto
topic_mentionLLYdiscussed_in_filing Healthcare & Bio
topic_mentionLLYdiscussed_in_filing Blockchain & Crypto
topic_mentionLLYdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-122025-12-310000059478-26-000013EDGAR58K words
2025-02-192024-12-310000059478-25-000067EDGAR—
2024-02-212023-12-310000059478-24-000065EDGAR—
2023-02-222022-12-310000059478-23-000082EDGAR—
2022-02-232021-12-310000059478-22-000068EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-10-302025-09-300000059478-25-000254EDGAR23K words
2025-08-072025-06-300000059478-25-000204EDGAR—
2025-05-012025-03-310000059478-25-000132EDGAR—
2024-10-302024-09-300000059478-24-000245EDGAR—
2024-08-082024-06-300000059478-24-000187EDGAR—
2024-04-302024-03-310000059478-24-000118EDGAR—
2023-11-022023-09-300000059478-23-000284EDGAR—
2023-08-082023-06-300000059478-23-000221EDGAR—
2023-04-272023-03-310000059478-23-000162EDGAR—
2022-11-012022-09-300000059478-22-000250EDGAR—
2022-08-042022-06-300000059478-22-000196EDGAR—
2022-04-292022-03-310000059478-22-000133EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-040000059478-26-000008EDGAR6K words
2025-11-210000059478-25-000271EDGAR—
2025-10-300000059478-25-000251EDGAR—
2025-08-200001193125-25-184093EDGAR—
2025-08-070000059478-25-000202EDGAR—
2025-05-080000059478-25-000138EDGAR—
2025-05-010000059478-25-000129EDGAR—
2025-02-120001193125-25-025057EDGAR—
2025-02-060000059478-25-000037EDGAR—
2025-01-140000059478-25-000005EDGAR—

70 total filings indexed. 43 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

cardiometabolic-health oncology immunology neuroscience united-states europe asia china

Company Identity

CIK0000059478
TickerLLY
ExchangeNYSE
SIC2834: Pharmaceutical Preparations
IncorporatedIN
HeadquartersIndianapolis, Indiana
Websitehttps://www.lilly.com
Listed1970-07-09

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 2aa970c458b0738bdbe2fa667db05fcec1c692da7b212ca41d8adf7cdc90e308
parent: e0f49779dc997d0caa48d670357cd8aff7a8ed2bd23f0ede813fb2cf593ff26f
content hash: 631bcfb847c86c50ab16f802e791ec159a9b0da6af6cbe6a4fe14afe67cd7d60
signed: 2026-04-13T04:46:03.508Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf